JP2023505227A - トリアゾール抗真菌化合物pc945の多形 - Google Patents

トリアゾール抗真菌化合物pc945の多形 Download PDF

Info

Publication number
JP2023505227A
JP2023505227A JP2022533459A JP2022533459A JP2023505227A JP 2023505227 A JP2023505227 A JP 2023505227A JP 2022533459 A JP2022533459 A JP 2022533459A JP 2022533459 A JP2022533459 A JP 2022533459A JP 2023505227 A JP2023505227 A JP 2023505227A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
water
polymorphic
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505227A5 (cg-RX-API-DMAC7.html
Inventor
ジョン ウォリス クリストファー
スティール ジェラルド
バッター スザンヌ
スレイマン オサマ
ノーザン ジュリアン
マイキーティウク ジョン
マーシャル ジェイミー
Original Assignee
プルモシデ リミテド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プルモシデ リミテド filed Critical プルモシデ リミテド
Publication of JP2023505227A publication Critical patent/JP2023505227A/ja
Publication of JP2023505227A5 publication Critical patent/JP2023505227A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022533459A 2019-12-06 2020-12-04 トリアゾール抗真菌化合物pc945の多形 Pending JP2023505227A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1917867.2 2019-12-06
GBGB1917867.2A GB201917867D0 (en) 2019-12-06 2019-12-06 Polymorphs
PCT/GB2020/053107 WO2021111142A1 (en) 2019-12-06 2020-12-04 Polymorphs of triazole antifungal compound pc945

Publications (2)

Publication Number Publication Date
JP2023505227A true JP2023505227A (ja) 2023-02-08
JP2023505227A5 JP2023505227A5 (cg-RX-API-DMAC7.html) 2023-12-13

Family

ID=69171938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533459A Pending JP2023505227A (ja) 2019-12-06 2020-12-04 トリアゾール抗真菌化合物pc945の多形

Country Status (26)

Country Link
US (2) US12491182B2 (cg-RX-API-DMAC7.html)
EP (2) EP4069690B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023505227A (cg-RX-API-DMAC7.html)
KR (1) KR20220110726A (cg-RX-API-DMAC7.html)
CN (1) CN114746415B (cg-RX-API-DMAC7.html)
AU (1) AU2020397613A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006259A2 (cg-RX-API-DMAC7.html)
CA (1) CA3155829A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001464A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022007808A2 (cg-RX-API-DMAC7.html)
DK (1) DK4069690T3 (cg-RX-API-DMAC7.html)
ES (1) ES3000984T3 (cg-RX-API-DMAC7.html)
FI (1) FI4069690T3 (cg-RX-API-DMAC7.html)
GB (1) GB201917867D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250042T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069799T2 (cg-RX-API-DMAC7.html)
IL (1) IL293401B1 (cg-RX-API-DMAC7.html)
LT (1) LT4069690T (cg-RX-API-DMAC7.html)
MX (1) MX2022006654A (cg-RX-API-DMAC7.html)
PL (1) PL4069690T3 (cg-RX-API-DMAC7.html)
PT (1) PT4069690T (cg-RX-API-DMAC7.html)
RS (1) RS66401B1 (cg-RX-API-DMAC7.html)
SA (1) SA522432879B1 (cg-RX-API-DMAC7.html)
SI (1) SI4069690T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400514T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021111142A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016087880A1 (en) 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound
CN117510488B (zh) * 2022-07-28 2025-12-05 博瑞制药(苏州)有限公司 一种硫酸艾沙康唑的制备方法
CN117330660A (zh) * 2023-09-14 2024-01-02 广州医科大学附属第一医院(广州呼吸中心) Uplc-ms/ms联用检测艾沙康唑的方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017536385A (ja) * 2014-12-05 2017-12-07 プルモシデ リミテド 抗真菌化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
AU2811689A (en) 1987-11-20 1989-06-14 Schering Corporation Tri-and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
DK0736030T3 (da) 1993-12-21 2001-10-29 Schering Corp Fungicide tetrahydrofuraner
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2199291T3 (es) 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
PL212985B1 (pl) 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu
EP2141159A1 (en) * 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017536385A (ja) * 2014-12-05 2017-12-07 プルモシデ リミテド 抗真菌化合物

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
PHARM STAGE, vol. 6, JPN6024041191, 2007, pages 48 - 53, ISSN: 0005438304 *
実験化学講座(続)2 分離と精製, JPN6024041188, 25 January 1967 (1967-01-25), pages 159 - 178, ISSN: 0005438308 *
新・薬剤学総論(改訂第3版), JPN6024041192, 10 April 1987 (1987-04-10), pages 111, ISSN: 0005438303 *
新製剤学, JPN6024041193, 25 April 1984 (1984-04-25), pages 102 - 103, ISSN: 0005438302 *
有機合成化学協会誌, vol. 65, JPN6024041187, 2007, pages 907 - 913, ISSN: 0005438306 *
第十六改正 日本薬局方, JPN6024041195, 2011, pages 64 - 68, ISSN: 0005438300 *
芦澤一英 他, 医薬品の多形現象と晶析の科学, JPN6024041189, 20 September 2002 (2002-09-20), JP, pages 3 - 16, ISSN: 0005438307 *
調剤学−基礎と応用−, JPN6024041194, 20 September 1977 (1977-09-20), pages 142 - 145, ISSN: 0005438301 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6024041190, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005438305 *

Also Published As

Publication number Publication date
KR20220110726A (ko) 2022-08-09
CN114746415B (zh) 2025-04-11
PT4069690T (pt) 2024-12-13
LT4069690T (lt) 2025-01-10
CN114746415A (zh) 2022-07-12
EP4509179A2 (en) 2025-02-19
HUE069799T2 (hu) 2025-04-28
CL2022001464A1 (es) 2023-03-24
IL293401B1 (en) 2026-08-01
MX2022006654A (es) 2022-09-07
US20260060980A1 (en) 2026-03-05
CO2022007808A2 (es) 2022-06-30
SMT202400514T1 (it) 2025-01-14
ES3000984T3 (es) 2025-03-04
SA522432879B1 (ar) 2025-01-26
EP4069690A1 (en) 2022-10-12
HRP20250042T1 (hr) 2025-03-14
US12491182B2 (en) 2025-12-09
WO2021111142A1 (en) 2021-06-10
DK4069690T3 (da) 2025-01-20
PL4069690T3 (pl) 2025-03-10
BR112022006259A2 (pt) 2022-06-21
FI4069690T3 (fi) 2025-01-21
SI4069690T1 (sl) 2025-03-31
IL293401A (en) 2022-07-01
EP4069690B1 (en) 2024-11-13
AU2020397613A1 (en) 2022-06-02
CA3155829A1 (en) 2021-06-10
US20230028714A1 (en) 2023-01-26
GB201917867D0 (en) 2020-01-22
EP4509179A3 (en) 2025-02-26
RS66401B1 (sr) 2025-02-28

Similar Documents

Publication Publication Date Title
US20260060980A1 (en) Polymorphs of triazole antifungal compound pc945
CN107001343B (zh) 抗真菌的化合物
EP3490978B1 (en) Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof
US10513511B2 (en) Aqueous suspension formulation comprising 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl) or a pharmaceutically acceptable salt thereof
HK40124005A (en) Polymorphs
EA048470B1 (ru) Полиморфы триазольного противогрибкового соединения pc945
HK40082086A (en) Polymorphs of triazole antifungal compound pc945
HK40082086B (en) Polymorphs of triazole antifungal compound pc945
HK40046347A (en) Antimycotic compound
HK40046347B (en) Antimycotic compound
HK40009059A (en) Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof
HK40009059B (en) Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof
BR112017020807B1 (pt) Composto 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-il)metil)-5-(2,4- difluorofenil)tetra-hidrofuran-3-il)metóxi)-3-metilfenil)piperazin-1-il)-n-(2- hidroxiciclo-hexil) benzamida antifúngica, seu processo de preparação, e composição farmacêutica
HK1252779B (en) Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1-yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof
NZ730861B2 (en) Antimycotic compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260803